PNU-120596 also weakly modulates recombinant rat α1β2γ2L GABAA receptors. At 50 μM, it increased low-GABA responses to 133 ± 11% of control (mean ± SEM; n = 5). Its potentiation concentration-response fits did not converge, and it reduced steady-state responses to saturating GABA. These findings limit broad claims of target exclusivity. [3]
Agonist-dependent potentiation and nAChR subtype comparison
Cell-based study · Xenopus oocytes expressing wild-type human α7, α4β2, α3β4 or α9α10 nAChRs [1]
PNU-120596 increased α7 agonist-evoked peak currents and prolonged responses. At the tested concentration, no detectable potentiation was found for the other three nAChR subtypes.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 μM PNU-120596
- Exposure duration
- 20 s pretreatment; 3 s agonist test pulses
- Method
- Two-electrode voltage clamp; agonist responses before and after PNU-120596
- Vehicle
- Compounds diluted in OR2 recording medium; no stock-solvent fraction specified for this selected assay
- Co-treatment
- ACh 100 μM or choline 1 mM for α7; subtype comparison used ACh 100 μM (α7), 50 μM (α4β2 and α3β4), or 10 μM (α9α10)
- Reported limits
- No numerical α7 fold increase estimated from bars. Figure 2C has inconsistent replicate descriptions, so its fitted ACh potency values are not adopted.
Methods and source locations
Compound reported in the paper: PNU-120596; Compound label in the paper: PNU-120596
Evidence concerns the named research compound in the reported model; it does not validate an Adooq batch or establish human efficacy.
Figure 2A–B,D; associated Results; Materials and Methods: Oocyte preparation and recording
Peak-current potentiation and response duration: Within-oocyte agonist controls followed by PNU-120596 exposure; subtype comparison in a separate oocyte batch — Figure 2A–B,D and associated Results; Materials and Methods: Oocyte preparation and recording
Transmembrane mutations reduce α7 potentiation
Cell-based study · Xenopus oocytes expressing rat wild-type or point-mutated α7 nAChRs [2]
Compared with wild-type α7, A225D and M253L markedly reduced maximal potentiation by PNU-120596. These functional determinants do not alone prove the physical location of a ligand-binding pocket.
Literature-Reported Treatment Conditions
- Treatment concentration
- PNU-120596 0.1–30 μM
- Exposure duration
- Not specified in the selected main-text mutagenesis protocol
- Method
- Two-electrode voltage clamp
- Vehicle
- Recording solvent fraction not specified in the selected main text
- Co-treatment
- Submaximal (EC20) ACh, defined separately for receptor constructs
- Reported limits
- SI Fig. S2 was not retrieved; exact construct-specific EC20 concentrations and any additional SI protocol details are unavailable here.
Methods and source locations
Compound reported in the paper: PNU-120596; Compound label in the paper: PNU-120596
Evidence concerns the named research compound in the reported model; it does not validate an Adooq batch or establish human efficacy.
Figure 2; Table 1; associated Results; Methods Materials and Xenopus Oocyte Electrophysiology
Maximal fold potentiation of EC20 ACh responses: Concentration-response electrophysiology; Table 1 values are mean ± SEM from three to seven independent experiments; Figure 2 describes five to seven different oocytes per curve — Results: Identification of Amino Acids Required for Allosteric Modulation; Table 1; Figure 2
Weak GABAA modulation with concentration-response limits
Cell-based study · Xenopus laevis oocytes expressing rat α1β2γ2L GABAA receptors [3]
PNU-120596 weakly potentiated submaximal GABA responses and very weakly directly activated the receptor. Potentiation fits failed to converge. With saturating GABA, the steady-state current decreased instead of increasing.
Literature-Reported Treatment Conditions
- Treatment concentration
- 50 μM for direct activation and low-/saturating-GABA comparisons; 1–50 μM in potentiation concentration-response measurements
- Exposure duration
- 30–60 s direct activation; 20–40 s concentration-response applications, separated by 1–3 min washouts
- Method
- Two-electrode voltage clamp at −60 mV
- Vehicle
- Electrophysiology stock solvent/final vehicle fraction not specified in the read Methods; the 0.1% DMSO/HBS formulation belongs to the separate fluorescence assay
- Co-treatment
- Low GABA (2–5 μM for Figure 4; 2–4 μM in Figure 5 caption); saturating GABA 1 mM; reference response 1 mM GABA + 50 μM propofol
- Reported limits
- No valid PNU-120596 potentiating EC50 obtained; no direct inference of in vivo GABAA contribution.
Methods and source locations
Compound reported in the paper: PNU-120596; Compound label in the paper: PNU-120596
Evidence concerns the named research compound in the reported model; it does not validate an Adooq batch or establish human efficacy.
Figures 3–6 and associated Results; Methods: electrophysiological recordings, data/statistical analysis, Materials
Potentiation of low-GABA steady-state response: Peak GABA + PNU-120596 current divided by preceding GABA steady-state current; 100% means no change — Results α7-PAMs activate and potentiate the α1β2γ2L GABAAR; Figure 4
Direct activation relative to reference response: Normalized to peak response to 1 mM GABA + 50 μM propofol in the same oocytes — Figure 3 and associated Results; electrophysiological Methods
PNU-120596 potentiation concentration-response fit: Coapplication of 1–50 μM PNU-120596 with low GABA — Figure 5 and associated Results
Steady-state response with saturating GABA: Coapplication during steady-state response to 1 mM GABA; individual replicate count not specified in the adjacent sentence — Figure 6 and associated Results